Molecular Neuropsychiatry最新文献

{"title":"Social Isolation Rearing Induces Neuropsychiatric Diseases: Updated Overview.","authors":"Hamidreza Famitafreshi,&nbsp;Morteza Karimian","doi":"10.1159/000495659","DOIUrl":"https://doi.org/10.1159/000495659","url":null,"abstract":"<p><p>Neuropsychiatric and neurologic diseases cause a great burden for individuals, families, and societies. Social isolation rearing can trigger a variety of psychiatric diseases. New advances suggest that epigenetic factors along with other neurochemical changes can be an important topic in neuropsychiatric diseases. It is thought that the prevention of social isolation rearing that occurs around birth can reduce the occurrence of neuropsychiatric diseases. It has been suggested that the environment can induce epigenetic alternation. So, for the diagnosis of a proportion of neuropsychiatric diseases, assessing epigenetic factors may be helpful. Also, apart from epigenetic factors, new advances have been made about new mechanisms of and treatments for such a disorder.</p>","PeriodicalId":18957,"journal":{"name":"Molecular Neuropsychiatry","volume":" ","pages":"190-195"},"PeriodicalIF":0.0,"publicationDate":"2019-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000495659","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37008443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Front & Back Matter","authors":"W. Wiersinga, G. Kahaly, V. Blanchette, L. Brandão, V. Breakey, S. Revel-Vilk, W. Byerley, T. Petryshen","doi":"10.1159/000497750","DOIUrl":"https://doi.org/10.1159/000497750","url":null,"abstract":"","PeriodicalId":18957,"journal":{"name":"Molecular Neuropsychiatry","volume":"24 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91510764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contents Vol. 4, 2018","authors":"W. Byerley, J. Gelernter, T. Petryshen, A. Sawa, C. Abdallah, K. Brennand, M. Filiou, S. Hyman, S. Jeste, Rakesh Karmacharya, T. Kash, J. Kelsoe, James L. Kennedy, Bryan W. Luikart, C. McClung","doi":"10.1159/000497220","DOIUrl":"https://doi.org/10.1159/000497220","url":null,"abstract":"Chadi G. Abdallah – Yale University, New Haven, USA Jyothi Arikkath – University of Nebraska Medical Center, Omaha, USA Dimitrios Avramopoulos – Johns Hopkins University, Baltimore, USA Mounira Banasr – University of Toronto, Toronto, Canada Cathy L. Barr – Toronto Western Research Institute, Toronto, Canada Carrie Bearden – UCLA Semel Institute, Los Angeles, USA Nicholas Bray – MRC Centre for Neuropsychiatric Genetics & Genomics, Cardiff, UK Kristen Brennand – Icahn School of Medicine at Mount Sinai, New York, USA Elisa Brietzke – Toronto Western Hospital, Toronto, Canada Andres L. Buonanno – Porter Neuroscience Research Center, Bethesda, USA Kelly Cosgrove – Yale University, New Haven, USA Lynn E. DeLisi – Harvard Medical School, Boston, USA Joao Luciano De Quevedo – University of Texas Health Science Center, Houston, USA Bernie Devlin – University of Pittsburgh, Pittsburgh, USA Jubao Duan – University of Chicago, Chicago, USA Donard Dwyer – LSU Health Shreveport, Shreveport, USA Michaela D. Filiou – Max Planck Institute of Psychiatry, Munich, Germany Steven Finkbeiner – University of California, San Francisco, USA Kenneth N. Fish – University of Pittsburgh, Pittsburgh, USA Jan Fullerton – NeuRA, Randwick, Australia Joshua Gordon – National Institute of Mental Health, Bethesda, USA Marco A. Grados –Johns Hopkins University, Baltimore, USA Tiffany Greenwood – UC San Diego, La Jolla, USA Jeremy Hall – Cardiff University, Cardiff, United Kingdom Steven E. Hyman – Harvard University, Cambridge, USA Andrew Jaffe – Johns Hopkins University, Baltimore, USA Paul Jenkins – University of Michigan, Ann Arbor, USA Shafali Spurling Jeste – UCLA Semel Institute, Los Angeles, USA Mandy Johnstone – Royal Edinburgh Hospital, Edinburgh, UK Official Journal of the","PeriodicalId":18957,"journal":{"name":"Molecular Neuropsychiatry","volume":"41 1","pages":"I - IV"},"PeriodicalIF":0.0,"publicationDate":"2019-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84965408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cell Type-Specific Gene Expression of Alpha 5 Subunit-Containing Gamma-Aminobutyric Acid Subtype A Receptors in Human and Mouse Frontal Cortex.","authors":"Xiyue Hu,&nbsp;Brad R Rocco,&nbsp;Corey Fee,&nbsp;Etienne Sibille","doi":"10.1159/000495840","DOIUrl":"https://doi.org/10.1159/000495840","url":null,"abstract":"<p><p>Converging evidence suggests that deficits in somatostatin (SST)-expressing neuron signaling contributes to major depressive disorder. Preclinical studies show that enhancing this signaling, specifically at α5 subunit-containing γ-ami-nobutyric acid subtype A receptors (α5-GABA^ARs), provides a potential means to overcome low SST neuron function. The cortical microcircuit comprises multiple subtypes of inhibitory γ-aminobutyric acid (GABA) neurons and excitatory pyramidal cells (PYCs). In this study, multilabel fluorescence in situ hybridization was used to characterize α5-GABA^AR gene expression in PYCs and three GABAergic neuron subgroups - vasoactive intestinal peptide (VIP)-, SST-, and parvalbumin (PV)-expressing cells - in the human and mouse frontal cortex. Across species, we found the majority of gene expression in PYCs (human: 39.7%; mouse: 54.14%), less abundant expression in PV neurons (human: 20%; mouse: 16.33%), and no expression in VIP neurons (0%). Only human SST cells expressed GABRA5, albeit at low levels (human: 8.3%; mouse: 0%). Together, this localization suggests potential roles for α5-GABA^ARs within the cortical microcircuit: (1) regulators of PYCs, (2) regulators of PV cell activity across species, and (3) sparse regulators of SST cell inhibition in humans. These results will advance our ability to predict the effects of pharmacological agents targeting α5-GABA^ARs, which have shown therapeutic potential in preclinical animal models.</p>","PeriodicalId":18957,"journal":{"name":"Molecular Neuropsychiatry","volume":" ","pages":"204-215"},"PeriodicalIF":0.0,"publicationDate":"2019-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000495840","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37008445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neurobiological and Neurophysiological Mechanisms Underlying Nicotine Seeking and Smoking Relapse.","authors":"Heath D Schmidt,&nbsp;Laura E Rupprecht,&nbsp;Nii A Addy","doi":"10.1159/000494799","DOIUrl":"10.1159/000494799","url":null,"abstract":"<p><p>Tobacco-related morbidity and mortality continue to be a significant public health concern. Unfortunately, current FDA-approved smoking cessation pharmacotherapies have limited efficacy and are associated with high rates of relapse. Therefore, a better understanding of the neurobiological and neurophysiological mechanisms that promote smoking relapse is needed to develop novel smoking cessation medications. Here, we review preclinical studies focused on identifying the neurotransmitter and neuromodulator systems that mediate nicotine relapse, often modeled in laboratory animals using the reinstatement paradigm, as well as the plasticity-dependent neurophysiological mechanisms that facilitate nicotine reinstatement. Particular emphasis is placed on how these neuroadaptations relate to smoking relapse in humans. We also highlight a number of important gaps in our understanding of the neural mechanisms underlying nicotine reinstatement and critical future directions, which may lead toward the development of novel, target pharmacotherapies for smoking cessation.</p>","PeriodicalId":18957,"journal":{"name":"Molecular Neuropsychiatry","volume":"4 4","pages":"169-189"},"PeriodicalIF":0.0,"publicationDate":"2019-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000494799","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9501950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research Domain Criteria: Cutting Edge Neuroscience or Galen's Humors Revisited?","authors":"Christopher A Ross,&nbsp;Russell L Margolis","doi":"10.1159/000493685","DOIUrl":"https://doi.org/10.1159/000493685","url":null,"abstract":"<p><p>The Research Domain Criteria (RDoC) scheme has guided the research agenda of the National Institute of Mental Health for the past decade. The essence of RDoC is its dimensional conception of mental illness, with the assumption that psychopathology is a manifestation of extremes along axes of neuropsychological variation. Research, it follows, should emphasize normal neuropsychological function and its associated neurocircuitry. We argue that RDoC, dressed in terms of modern neurobiology, is in fact a return to the humoral theory of Galen, a dimensional approach in which physical and mental health requires a balance of the four basic bodily humors (blood, black bile, yellow bile, and phlegm). The RDoC/Galenic approach may be useful in understanding those conditions best understood as extremes along a continuum, such as personality disorders. However, we contend that for the most severe psychiatric disorders - categorically defined diseases such as schizophrenia, bipolar disorder, and autism - RDoC's Galenic dimensionalism is a retreat from the biomedical approach that seeks to find rational therapeutic targets by identifying etiologic factors and pathogenic pathways. Abandoning this medical model now, in the context of remarkable advances in genetics, neuroimaging, and neuroscience, is a major setback for the advancement of scientific psychiatry.</p>","PeriodicalId":18957,"journal":{"name":"Molecular Neuropsychiatry","volume":"4 3","pages":"158-163"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000493685","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36908012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In the Realm of Psychoneuroimmunology: The Role of Celecoxib as an Add-On Treatment for Bipolar Mania.","authors":"Mohammed Al-Alawi,&nbsp;Hamed Al Sinawi,&nbsp;Roshe Rashid","doi":"10.1159/000494700","DOIUrl":"10.1159/000494700","url":null,"abstract":"<p><p>Bipolar affective disorder (BPAD) is a chronic debilitating psychiatric illness seriously affecting the quality of patients' life. The available treatment is effective in about half of those suffering from the illness. The neurobiological basis of the disorder is not fully unraveled. With such lacunae, attempts have been made to decipher the underlying neuroimmunological process of the illness as is the case with other mental disorders. As a result, some inflammatory processes have been implicated in the etiology of BPAD, as described in this communication. Subsequently, the role of anti-inflammatory agents such as celecoxib was investigated by treating different phases of BPAD. Given the promising outcomes of several trials and reviews, celecoxib has gained momentum and has been recommended as an adjunctive treatment by some guidelines for treating resistant BPAD cases. This brief communication highlights some of the caveats in the randomized trials using celecoxib as an add-on treatment in bipolar mania specifically, which need to be addressed in future work.</p>","PeriodicalId":18957,"journal":{"name":"Molecular Neuropsychiatry","volume":"4 3","pages":"164-167"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000494700","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36908013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential Role of Antipsychotic-Galantamine-Memantine Combination in the Treatment of Positive, Cognitive, and Negative Symptoms of Schizophrenia.","authors":"Maju Mathew Koola","doi":"10.1159/000494495","DOIUrl":"10.1159/000494495","url":null,"abstract":"<p><p>Schizophrenia is, in part, a cognitive illness. There are no approved medications for cognitive impairments associated with schizophrenia (CIAS) and primary negative symptoms. Cholinergic and glutamatergic systems, alpha-7 nicotinic acetylcholine (α-7nACh) and <i>N</i>-methyl-D-aspartate (NMDA) receptors, kynurenic acid (KYNA), and mismatch negativity have been implicated in the pathophysiology of CIAS and negative symptoms. Galantamine is an acetylcholinesterase inhibitor that is also a positive allosteric modulator at the α4β2 and α7nACh receptors. Memantine is a noncompetitive NMDA receptor antagonist. Galantamine and memantine alone and in combination were effective for cognition in animals and people with Alzheimer's disease. The objective of this article is to critically dissect the published randomized controlled trials with galantamine and memantine for CIAS to highlight the efficacy signal. These studies may have failed to detect a clinically meaningful efficacy signal due to limitations, methodological issues, and possible medication nonadherence. There is evidence from a small open-label study that the galantamine-memantine combination may be effective for CIAS with kynurenine pathway metabolites as biomarkers to detect the severity of cognitive impairments. Given that there are no available treatments for cognitive impairments and primary negative symptoms in schizophrenia, testing of this \"five-pronged strategy\" (quintuple hypotheses: dopamine, nicotinic-cholinergic, glutamatergic/NMDA, GABA, and KYNA) is a \"low-risk high-gain\" approach that could be a major breakthrough in the field. The galantamine-memantine combination has the potential to treat positive, cognitive, and negative symptoms, and targeting the quintuple hypotheses concurrently may lead to a major scientific advancement - from antipsychotic treatment to antischizophrenia treatment.</p>","PeriodicalId":18957,"journal":{"name":"Molecular Neuropsychiatry","volume":"4 3","pages":"134-148"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000494495","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36853504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regulation of the Expression of the Psychiatric Risk Gene <i>Cacna1c</i> during Associative Learning.","authors":"Lucy Sykes, Nicholas E Clifton, Jeremy Hall, Kerrie L Thomas","doi":"10.1159/000493917","DOIUrl":"10.1159/000493917","url":null,"abstract":"<p><p><i>CACNA1C</i> encodes the Ca_v1.2 L-type voltage-gated calcium channel. Generic variation in CACNA1C has been consistently identified as associated with risk for psychiatric disorders including schizophrenia, bipolar disorder, major depressive disorder and autism. Psychiatric risk loci are also enriched for genes involved in the regulation of synaptic plasticity. Here, we show that the expression of <i>Cacna1c</i> is regulated in the rat hippocampus after context exposure, contextual fear conditioning and fear memory retrieval in a manner that correlates to specific memory processes. Using quantitative in situ hybridisation, the expression was down-regulated in CA1 by brief exposure to a novel context and to a conditioned context, and up-regulated in the dentate gyrus after contextual fear conditioning. No changes were measured after prolonged context exposure followed by conditioning, a procedure that retards fear conditioning (latent inhibition), nor with fear memory recall leading to extinction. These results are consistent with a selective role for Ca_v1.2 in the consolidation of context memory and contextual fear memory, and with processes associated with the maintenance of the fear memory after recall. The dysregulation of <i>CACNA1C</i> may thus be related to associative memory dysfunction in schizophrenia and other psychiatric disorders.</p>","PeriodicalId":18957,"journal":{"name":"Molecular Neuropsychiatry","volume":"4 3","pages":"149-157"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323400/pdf/mnp-0004-0149.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36853503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>VRK2</i>, a Candidate Gene for Psychiatric and Neurological Disorders.","authors":"Ming Li,&nbsp;Weihua Yue","doi":"10.1159/000493941","DOIUrl":"10.1159/000493941","url":null,"abstract":"<p><p>Recent large-scale genetic approaches, such as genome-wide association studies, have identified multiple genetic variations that contribute to the risk of mental illnesses, among which single nucleotide polymorphisms (SNPs) within or near the vaccinia related kinase 2 (<i>VRK2</i>) gene have gained consistent support for their correlations with multiple psychiatric and neurological disorders including schizophrenia (SCZ), major depressive disorder (MDD), and genetic generalized epilepsy. For instance, the genetic variant rs1518395 in <i>VRK2</i> showed genome-wide significant associations with SCZ (35,476 cases and 46,839 controls, <i>p</i> = 3.43 × 10^-8) and MDD (130,620 cases and 347,620 controls, <i>p</i> = 4.32 × 10^-12) in European populations. This SNP was also genome-wide significantly associated with SCZ in Han Chinese population (12,083 cases and 24,097 controls, <i>p</i> = 3.78 × 10^-13), and all associations were in the same direction of allelic effects. These studies highlight the potential roles of <i>VRK2</i> in the central nervous system, and this gene therefore might be a good candidate to investigate the shared genetic and molecular basis between SCZ and MDD, as it is one of the few genes known to show genome-wide significant associations with both illnesses. Furthermore, the <i>VRK2</i> gene was found to be involved in multiple other congenital deficits related to the malfunction of neurodevelopment, adding further support for the involvement of this gene in the pathogenesis of these neurological and psychiatric illnesses. While the precise function of <i>VRK2</i> in these conditions remains unclear, preliminary evidence suggests that it may affect neuronal proliferation and migration via interacting with multiple essential signaling pathways involving other susceptibility genes/proteins for psychiatric disorders. Here, we have reviewed the recent progress of genetic and molecular studies of <i>VRK2</i>, with an emphasis on its role in psychiatric illnesses and neurological functions. We believe that attention to this important gene is necessary, and further investigations of <i>VRK2</i> may provide hints into the underlying mechanisms of SCZ and MDD.</p>","PeriodicalId":18957,"journal":{"name":"Molecular Neuropsychiatry","volume":"4 3","pages":"119-133"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1159/000493941","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36853502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}